Petrelintide, a long-acting human amylin analogue, provides clinically meaningful weight loss in obese adults over 28 to 42 weeks of treatment.
Once-weekly subcutaneous administration achieves up to approximately 10.7% bodyweight reduction compared with 1.7% with placebo.
Gastrointestinal side effects are predominantly mild nausea during dose escalation, with low rates of vomiting, diarrhea, or constipation similar to placebo.
This phase 2 trial supports further development of petrelintide as a novel obesity treatment distinct from incretin-based therapies.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
